Similarly, tirzepatide, a dual GLP-1R and GIP receptor agonist, does not seem to cross the BBB efficiently (Rhea et al., 2024)
The Regulatory Landscape of Retatrutide FDA Status, Legality, and the "Research" Red Flag As of early 2026, Retatrutide occupies a unique space in the medical world: it is the most anticipated drug in the history of obesity medicine, yet it remains unapproved for commercial use
Your prescribing provider determines the schedule based on your specific therapeutic goal and cycle structure
Correlations (simple and partial) between fatigue and S-5-HT levels were assessed using Spearman rho correlation coefficients
If you have experience with semaglutide or tirzepatide , you already have a reference point for GLP-1 mediated effects